American Shared Hospital Services (AMS): 2025 Year-End Update

American Shared Hospital Services (AMS) is in the middle of a major identity shift. The company is moving away from its traditional, low-maintenance business of leasing medical equipment to hospitals and toward a "direct patient care" model where AMS owns and operates its own radiation therapy centers. While this could lead to higher long-term revenue, it is currently a costly and risky transition.

1. The Big Shift: What’s Happening?

AMS is trading a predictable, hands-off business model for a more complex, hands-on service model.

• The Old Business: AMS extended its lease with Orlando Health for its Proton Beam therapy system through 2033. This is a positive sign, as it secures steady income from their legacy business.
• The Financial Reality: 2025 was a tough year. AMS reported a $1.55 million loss, a sharp decline from the $2.19 million profit in 2024. Total revenue fell 14% to $14.8 million.
• The "Why": Revenue dropped because several older equipment leases expired and weren't renewed. At the same time, costs spiked because the company is pouring money into building new, company-owned centers, such as the new facility in Rhode Island.

2. The Financial Pressure: Why It Matters

The transition is putting a significant strain on the company’s bank account.

• Cash Burn: AMS started 2025 with $11.3 million in cash but ended the year with only $3.7 million.
• Adjusted EBITDA: The company reported an "Adjusted EBITDA" of $5.46 million (down from $7.12 million in 2024). This figure highlights the company's underlying cash-generating power, but it’s important to remember that it ignores the massive capital expenditures required to build these new centers.
• Debt Risk: This is the most critical point for investors: AMS missed certain financial requirements tied to its bank loans. They are currently in negotiations to avoid a default. If they can’t reach an agreement, the bank could demand immediate repayment of the $8.2 million loan balance. The company didn't provide much detail on the progress of these talks, so this remains a major "watch item."

3. What Should Investors Watch?

AMS is essentially a startup again, but with the overhead of a public company. To decide if this is an opportunity or a risk, keep an eye on these two things:

• The Debt Agreement: The company’s survival depends on finalizing a new credit agreement with its lender. Any news regarding more flexible terms or a resolution to the current default risk will be the most important indicator of the company's stability.
• The "Burn Rate": With only $3.7 million in cash left, the clock is ticking. The company must prove that its new centers can attract enough patients to cover their own operating costs before the cash runs out.

Bottom Line for Your Portfolio

AMS is currently in a "high-risk, high-reward" phase. The shift to direct patient care could eventually lead to higher margins, but the current reality is a shrinking cash pile and a looming debt negotiation.

If you are considering an investment, ask yourself: Do I believe these new centers will become profitable fast enough to offset the cash burn and satisfy the bank? If the answer isn't clear, you may want to wait for the next quarterly update to see if the company has secured its debt and stabilized its cash flow.